Integrating Blood Pressure Control With Multi-Class Kidney Protective Agents in Diabetic Kidney Disease

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Diabetic kidney disease (DKD) significantly increases risks for chronic kidney disease progression, cardiovascular events, and mortality.
• Blood pressure (BP) control is crucial for managing DKD, but treatment is complicated by new kidney-protective medications.

Purpose of the Study:

• To review the evolving landscape of antihypertensive and kidney-protective therapies in DKD management.
• To discuss the integration of novel agents like SGLT2 inhibitors, finerenone, and incretin-based therapies with traditional RAAS blockade.
• To highlight the need for individualized treatment approaches and further research on optimal combination strategies.

Main Methods:

• Review of recent clinical trials and guidelines on BP management in DKD.
• Analysis of the mechanisms and effects of various antihypertensive and disease-modifying agents.
• Discussion of the balance between cardiovascular/renal benefits and potential harms.

Main Results:

• Contemporary DKD management incorporates RAAS blockade, SGLT2 inhibitors, finerenone, and incretin-based therapies.
• These agents provide BP lowering and cardiorenal benefits through complementary mechanisms.
• Intensive BP targets show benefit in some high-risk groups, but kidney-related harm remains a consideration.

Conclusions:

• An individualized, pragmatic approach integrating novel disease-modifying therapies with conventional antihypertensives is warranted for DKD.
• Optimal sequencing and combination strategies require further investigation through dedicated clinical trials.
• Future research should focus on maximizing long-term kidney and cardiovascular protection while ensuring safe BP control in DKD.